Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 3
1993 1
2000 4
2002 2
2003 1
2004 2
2007 3
2008 1
2009 3
2010 1
2011 1
2012 1
2015 2
2016 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Advances in the biology and treatment of oligodendrogliomas.
van den Bent MJ. van den Bent MJ. Curr Opin Neurol. 2004 Dec;17(6):675-80. doi: 10.1097/00019052-200412000-00006. Curr Opin Neurol. 2004. PMID: 15542975 Review.
Despite the large increase in knowledge on the molecular abnormalities in OD, the therapeutic options for these tumors have not improved significantly since the introduction of temozolomide. ...SUMMARY: The progress in the understanding of genetic and molecular a …
Despite the large increase in knowledge on the molecular abnormalities in OD, the therapeutic options for these tumors have no …
Genetic evaluation of inherited motor/sensory neuropathy.
Chance PF. Chance PF. Suppl Clin Neurophysiol. 2004;57:228-42. doi: 10.1016/s1567-424x(09)70360-5. Suppl Clin Neurophysiol. 2004. PMID: 16106622 Review.
Charcot-Marie-Tooth neuropathy type 1 (CMT1) is a genetically heterogeneous group of chronic demyelinating polyneuropathies with loci mapping to chromosome 17 (CMT1A), chromosome 1 (CMT1B), chromosome 16 (CMT1C) and chromosome 10 (CMT1D). ...
Charcot-Marie-Tooth neuropathy type 1 (CMT1) is a genetically heterogeneous group of chronic demyelinating polyneuropathies with loci mappin …
Pyruvate kinase deficiency: the genotype-phenotype association.
Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Zanella A, et al. Blood Rev. 2007 Jul;21(4):217-31. doi: 10.1016/j.blre.2007.01.001. Epub 2007 Mar 13. Blood Rev. 2007. PMID: 17360088 Review.
Red cell pyruvate kinase (PK) deficiency is the most frequent enzyme abnormality of glycolysis causing chronic non-spherocytic haemolytic anaemia. ...Erythrocyte PK is synthesised under the control of the PK-LR gene located on chromosome 1. One hundred eighty …
Red cell pyruvate kinase (PK) deficiency is the most frequent enzyme abnormality of glycolysis causing chronic non-spherocytic haemol …
Genetic screening and evaluation for chromosomal abnormalities of infertile males in Jilin Province, China.
Zhang M, Fan HT, Zhang QS, Wang XY, Yang X, Tian WJ, Li RW. Zhang M, et al. Genet Mol Res. 2015 Dec 8;14(4):16178-84. doi: 10.4238/2015.December.8.7. Genet Mol Res. 2015. PMID: 26662410 Free article.
The most common chromosome abnormality was Klinefelter syndrome, and the study findings suggested that azoospermia and oligospermia may result from structural chromosomal abnormalities. Chromosome 1 was shown to be most commonly involved in male infert …
The most common chromosome abnormality was Klinefelter syndrome, and the study findings suggested that azoospermia and oligospermia m …
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group. Fonseca R, et al. Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1. Leukemia. 2009. PMID: 19798094 Free PMC article. Review.
A number of genetic progression factors have been identified including deletions of chromosomes 13 and 17 and abnormalities of chromosome 1 (1p deletion and 1q amplification). Other key drivers of cell survival and proliferation have also been identified such …
A number of genetic progression factors have been identified including deletions of chromosomes 13 and 17 and abnormalities of chr …
Cytogenetic technology--genotype and phenotype.
Ledbetter DH. Ledbetter DH. N Engl J Med. 2008 Oct 16;359(16):1728-30. doi: 10.1056/NEJMe0806570. Epub 2008 Sep 10. N Engl J Med. 2008. PMID: 18784093 No abstract available.
Characterization and clinical implications of marker chromosomes identified at prenatal diagnosis.
Li MM, Howard-Peebles PN, Killos LD, Fallon L, Listgarten E, Stanley WS. Li MM, et al. Prenat Diagn. 2000 Feb;20(2):138-43. Prenat Diagn. 2000. PMID: 10694686
Of those autosomal SMCs, five originated from chromosome 15, two from chromosome 18, one from chromosome 12 and one from chromosome 1. Among 16 marker chromosomes with adequate follow-up information, 50% were benign including four sex chromosome markers and four aut …
Of those autosomal SMCs, five originated from chromosome 15, two from chromosome 18, one from chromosome 12 and one from chromosome …
Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions.
Ney DE, Lassman AB. Ney DE, et al. Curr Oncol Rep. 2009 Jan;11(1):62-7. doi: 10.1007/s11912-009-0010-x. Curr Oncol Rep. 2009. PMID: 19080743 Review.
In addition, oligodendrogliomas are the first central nervous system neoplasm for which a specific molecular abnormality, allelic loss of 1p/19q (1p/19q loss), correlates with patient outcome in large-scale prospective clinical trials. ...
In addition, oligodendrogliomas are the first central nervous system neoplasm for which a specific molecular abnormality, allelic los …
Neuroblastoma. Effect of genetic factors on prognosis and treatment.
Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, Moley J, Nakagawara A, Saylors R, Scavarda N, et al. Brodeur GM, et al. Cancer. 1992 Sep 15;70(6 Suppl):1685-94. doi: 10.1002/1097-0142(19920915)70:4+<1685::aid-cncr2820701607>3.0.co;2-h. Cancer. 1992. PMID: 1325279
These include: (1) loss of heterozygosity (LOH) for the short arm of chromosome 1, including band 1p36; (2) amplification of the N-myc protooncogene; (3) hyperdiploidy, or near triploidy; and (4) defects in expression or function of the nerve growth factor receptor …
These include: (1) loss of heterozygosity (LOH) for the short arm of chromosome 1, including band 1p36; (2) amplification of t …
Next-generation sequencing analysis of embryos from mosaic patients undergoing in vitro fertilization and preimplantation genetic testing.
Luo K, Lan Y, Xie P, Gong F, Xiong B, Tan Y, Zhou S, Yang Z, Lin G, Hu L. Luo K, et al. Fertil Steril. 2019 Aug;112(2):291-297.e3. doi: 10.1016/j.fertnstert.2019.03.035. Epub 2019 May 24. Fertil Steril. 2019. PMID: 31133385 Free article.
Of these 153 embryos, 2 (1.31%) had an abnormal copy number of X chromosome, 1 had mosaicism with 46,XN,+X(mosaic, 40%), 1 (0.65%) had an extra Y chromosome, 3 (1.96%) exhibited both X chromosomal and autosomal abnormalities, and 4 (2.61%) exhibited de …
Of these 153 embryos, 2 (1.31%) had an abnormal copy number of X chromosome, 1 had mosaicism with 46,XN,+X(mosaic, 40%) …
26 results